MedTrace Logo

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

NCT03428646 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 858

Last updated 2025-12-29

No results posted yet for this study

Summary

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Dupilumab

Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.

Sponsors & Collaborators

Principal Investigators

  • Medical Affairs · Regeneron Pharmaceuticals

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-06
Primary Completion
2027-03-30
Completion
2027-03-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03428646 on ClinicalTrials.gov